WELLMARKER BIO

wellmarker-bio-logo

Their Company has developed a biomarker-based cancer drugs based on accumulated developmental experience and know-how. They have a new drug development institute including synthetic and bio-research and management support center. Utilizing R&D infrastructure from Asan Medical Center in Seoul Republic of Korea they are focusing on developing new drugs that overcome resistance of existing therapeutic approaches. Additionally they are focusing on developing first-in-class biomarker-based drugs for medical unmet needs in various cancers such as colon cancer, lung cancer and liver cancer.

#Website #More

WELLMARKER BIO

Social Links:

Industry:
Biotechnology Medical Pharmaceutical

Founded:
2016-12-22

Address:
Seoul, Seoul-t'ukpyolsi, South Korea

Country:
South Korea

Website Url:
http://www.wmbio.co

Total Employee:
51+

Status:
Active

Contact:
+82-2-6952-1631

Email Addresses:
[email protected]

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Content Delivery Network Nginx JsDelivr AJAX Libraries API Korea Telecom Cafe24 DNS


Official Site Inspections

http://www.wmbio.co Semrush global rank: 8.25 M Semrush visits lastest month: 346

  • Host name: 183.111.182.232
  • IP address: 183.111.182.232
  • Location: South Korea
  • Latitude: 37.5112
  • Longitude: 126.9741
  • Timezone: Asia/Seoul

Loading ...

More informations about "Wellmarker Bio"

WMBIO

๋” ๊ฑด๊ฐ•ํ•œ ์„ธ์ƒ์„ ์œ„ํ•œ ๋…ธ๋ ฅ. ์›ฐ๋งˆ์ปค๋ฐ”์ด์˜คใˆœ๋Š” ๋ฏธ์ถฉ์กฑ ์˜๋ฃŒ์ˆ˜์š” ํ•ด๊ฒฐ์„ ์œ„ํ•ด ์น˜๋ฃŒ๋ฐ˜์‘ ์˜ˆ์ธก ๋ฐ”์ด์˜ค๋งˆ์ปค(Predictive Biomarker) ๊ธฐ๋ฐ˜์˜ ํ•ญ์•”์ œ๋ฅผ ๊ฐœ๋ฐœํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ์„œ์šธ์•„์‚ฐ๋ณ‘์›์˜ โ€ฆSee details»

Wellmarker Bio - Crunchbase Company Profile & Funding

Contact Email [email protected] Phone Number +82-2-6952-1631 Their Company has developed a biomarker-based cancer drugs based on accumulated developmental experience โ€ฆSee details»

Wellmarker Bio (WMBIO) - LinkedIn

Wellmarker Bio (WMBIO) | 136 followers on LinkedIn. Develops anticancer drugs based on predictive biomarkers with unmet needs | Wellmarker Bio is a spin-off company from Seoul Asan Medical Center ...See details»

Wellmarker Bio Co., Ltd. (Wellmarker Bio Co., Ltd.) - ่ฏ็‰ฉ็ฎก็บฟ_ไธ“ โ€ฆ

SEOUL, South Korea , Feb. 7, 2023 /PRNewswire/ -- Wellmarker Bio Co., Ltd (WMBIO) (CEO: Dong-Hoon Jin, Department of Convergence Medicine, Ulsan College of Medicine and Asan โ€ฆSee details»

Wellmarker Bio Company Profile | Management and Employees โ€ฆ

Www.wmbio.co Wellmarker Bio Profile and History Wellmarker Bio, the company that specializes in first-in-class anticancer drug development was introduced as an innovative growth company โ€ฆSee details»

Wellmarker Bio signs MoU with Isogenica for the โ€ฆ

May 30, 2022 Wellmarker Bio Co., Ltd (WMBIO), the first company to be spun out from the renowned Asan Medical Center, Koreaโ€™s largest hospital, focuses on the development of novel anticancer drugs derived from comprehensive โ€ฆSee details»

Wellmarkerbio (WMBIO) - VentureRadar

Website: https://wmbio.co. Pioneers the development of anticancer drugs using predictive biomarkers, aiming to optimize treatment responses and address unmet medical needs. ...See details»

WellMarker Bioโ€”developing fit-for-purpose biomarkers and novel ...

WellMarker Bio Co., Ltd www.wmbio.co WellMarker Bioโ€”developing fit-for-purpose biomarkers and novel therapies for cancer Seoul-based WellMarker Bio is developing a deep pipeline of โ€ฆSee details»

Wellmarker Bio - Overview, News & Similar companies - ZoomInfo

Feb 7, 2023 www.wmbio.co. Revenue $6.3 Million. Industry Business Services General Business Services . Recent News & Media. Wellmarker Bio Announces Clinical Trial โ€ฆSee details»

WellMarker Bio-developing fit-for-purpose biomarkers โ€ฆ

WellMarker Bio Co., Ltd (WMBIO), the first company to be spun out from the renowned Asan Medical Center, Koreaโ€™s largest hospital, focuses on the development of new anticancer drugs derived from ...See details»

์›ฐ๋งˆ์ปค๋ฐ”์ด์˜ค - ์œ„ํ‚ค๋ฐฑ๊ณผ, ์šฐ๋ฆฌ ๋ชจ๋‘์˜ ๋ฐฑ๊ณผ์‚ฌ์ „

์›ฐ๋งˆ์ปค๋ฐ”์ด์˜ค(wmbio Co. Ltd.)๋Š” ์น˜๋ฃŒ๋ฐ˜์‘ ์˜ˆ์ธก ๋ฐ”์ด์˜ค๋งˆ์ปค ๊ธฐ๋ฐ˜ ํ•ญ์•”์ œ ๊ฐœ๋ฐœ ์ „๋ฌธ ๋Œ€ํ•œ๋ฏผ๊ตญ ๊ธฐ์—…์œผ๋กœ ์„œ์šธ์•„์‚ฐ๋ณ‘์›์—์„œ ๋ถ„์‚ฌ๋˜์—ˆ๋‹ค [1] ๋Œ€ํ‘œ์ด์‚ฌ๋Š” ๋Œ€ํ•™๊ต์ˆ˜์ด์ž ์„œ์šธ์•„์‚ฐ๋ณ‘์› ์ดˆ๋Œ€ โ€ฆSee details»

Wellmarker Bio - Craft

Wellmarker Bio (WMBIO) is a company developing anticancer drugs based on predictive biomarkers. It is focused on solid tumors.See details»

WellmarkerBio receives approval for Phase I clinical trial from the ...

SEOUL, South Korea, March 3, 2021 /PRNewswire/ -- Wellmarker Bio(www.wmbio.co) announced that on February 23, 2021 the company received approval from the Australian โ€ฆSee details»

Wellmarker Bio Announces Clinical Trial Collaboration with MSD to ...

Feb 7, 2023 Wellmarker Bio Co., Ltd (WMBIO) is the first company to be spun out from the renowned Asan Medical Center, Korea's largest hospital. It focuses on the development of โ€ฆSee details»

WMBIO Trademark of Wellmarker Bio Co., LTD. - Registration โ€ฆ

Pharmaceutical agents affecting sensory organs; vaccines; vitamin preparations; nervines in the nature of pharmaceutical preparations to calm the nerves; digestives for pharmaceutical โ€ฆSee details»

WellmarkerBio receives approval for Phase I clinical trial from the ...

SEOUL, South Korea, March 3, 2021 /PRNewswire/ -- WellmarkerBio receives approval for Phase I clinical trial from the Australian Therapeutic Goods AdministrationSee details»

WellmarkerBio receives approval for Phase I clinical trial from the ...

SEOUL, South Korea, March 3, 2021 /PRNewswire/ -- Wellmarker Bio(www.wmbio.co) announced that on February 23, 2021 the company received approval f...See details»

Transforming the future of antibody therapeutics

Actively seeking partners for future co-develop-ment, particularly for clinical development, and for investment. ChongKunDangPharmaceuticalCorp ... (WMBIO), the first company to beSee details»

WM-A1-3389 - Drug Targets, Indications, Patents - Synapse

Once a drug candidate is at that stage, WMBIO would seek to find global pharmaceutical companies to partner with for co-development or licensing. For further information, visit: About โ€ฆSee details»

Meeting Abstract: 2020 ASCO Annual Meeting I - ASCO Publications

May 25, 2020 Background: CTC (Circulating tumor cells) has the advantage of being able to effectively investigate non-invasive diagnosis, prediction, and prognosis for non-surgical โ€ฆSee details»